Successful treatment of Langerhans'-cell histiocytosis with etanercept.
Henter
J I
JI
Karlén
J
J
Calming
U
U
Bernstrand
C
C
Andersson
U
U
Fadeel
B
B
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D000068800:Etanercept; D005260:Female; D006646:Histiocytosis, Langerhans-Cell / Q000188:drug therapy*; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007223:Infant; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D013256:Steroids; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D013256:Steroids; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept